Imunon (IMNN) Q4 2024 earnings summary

Executive summary

• Phase 2 OVATION 2 results for IMNN-001 in advanced ovarian cancer showed significant improvement in median overall survival, with a median OS of 13 months when combined with chemotherapy and even greater benefit with PARP inhibitors.

• Phase 3 pivotal trial (OVATION 3) is set to initiate in Q1/March 2025, with protocol and product ready, and strong FDA support including Fast Track and orphan drug designations.

• Additional translational data confirm strong dose response and favorable safety profile, with no elevation in systemic IL-12 or immune-related adverse events.

• PlaCCine DNA vaccine platform demonstrated promising immunogenicity and durability in COVID-19, with positive Phase 1 proof-of-concept data and plans to seek partnerships for further development.

• Leadership was strengthened with the appointment of Dr. Douglas V. Faller as Chief Medical Officer to support future clinical programs.

Financial highlights

• Cash and cash equivalents of $5.9 million as of December 31, 2024, expected to fund operations into late Q2 2025.

• 2024 R&D expenses were $11.6 million, with $1.4 million for OVATION 2, $1.4 million for PlaCCine, and $2.4 million for other clinical/regulatory costs.

• General and administrative expenses decreased to $7.5 million from $9.7 million in 2023.

• Net loss for 2024 was $18.6 million ($1.62 per share), improved from $19.5 million ($2.16 per share) in 2023.

• $9.1 million was raised through an at-the-market equity offering in July 2024.

Outlook and guidance

• Cash runway extends into late June 2025; company is actively seeking value-added financing, partnerships, and non-dilutive funding.

• OVATION 3 Phase 3 trial to enroll 500 patients, with two interim analyses and a final analysis planned.

• Potential for accelerated approval if interim data are strong, especially in HR-deficient subgroups.

• Focus remains on advancing IMNN-001 and TheraPlas, with PlaCCine positioned for out-licensing or partnership.

• Plans to seek partners for further development of the PlaCCine vaccine platform.